Presentations by Event

Presented at ASM Microbe, Atlanta, GA, June 2018

Addressing the Challenge of Gram-negative Permeation in Antibacterial Discovery

Thomas Durand-Reville, ASM Microbe 2018

Restoration of Sulbactam Activity by the Novel β-lactamase Inhibitor ETX2514 Against Recent Clinical Isolates of Acinetobacter baumannii, Including Extensively Drug-Resistant (XDR) Isolates Expressing OXA-237

Sarah McLeod, ASM Microbe 2018

Program(s): durlobactam (etx2514)

Evaluation of Pharmacokinetics/Pharmacodynamics of the Novel β-lactamase Inhibitor, ETX2514, in Combination with Sulbactam Against Acinetobacter baumannii

John O'Donnell, ASM Microbe 2018

Program(s): durlobactam (etx2514)

The Novel β-lactamase Inhibitor ETX1317 Effectively Restores the Activity of Cefpodoxime Against Extended Spectrum β-lactamase (ESBL)- and Carbapenemase-Expressing Enterobacteriaceae Isolated From Recent Urinary Tract Infections

Sarah McLeod, ASM Microbe 2018

Program(s): etx0282

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Adult Subjects

K.A. Rodvold (University of Illinois at Chicago), ASM Microbe 2018

Program(s): durlobactam (etx2514)

Presented at ID Week, San Diego, October 2017

Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β–lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β–lactamases

J. Lickliter, K. Lawrence, J. O’Donnell, and R. Isaacs, ID Week 2017

Program(s): durlobactam (etx2514)

Presented at ASM Microbe, New Orleans, June 2017

Cefpodoxime proxetil/ETX0282: A novel oral β-lactam/β-lactamase inhibitor combination to treat the emerging threat of multi-drug resistant Enterobacteriaceae

John O’Donnell, ASM Microbe 2017

Program(s): etx0282

The Antibacterial Activity of Sulbactam and the Novel β–lactamase Inhibitor ETX2514 Combined with Imipenem or Meropenem Against Recent Clinical Isolates of Acinetobacter baumannii and Pseudomonas aeruginosa

Sarah McLeod, ASM Microbe 2017

Program(s): durlobactam (etx2514)

The Antibacterial Activity of Cefpodoxime and the Novel β–lactamase Inhibitor ETX1317 Against Recent Clinical Isolates of β–lactamase-producing Enterobacteriaceae

Sarah McLeod, ASM Microbe 2017

Program(s): etx0282

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae

Thomas Durand-Reville, ASM Microbe 2017

Program(s): etx0282

Reversibility of β–lactamase inhibition by the broad-spectrum diazabicyclooctenone serine β–lactamase inhibitor ETX2514

Adam Shapiro, ASM Microbe 2017

Program(s): durlobactam (etx2514)